Revance Therapeutics Extends Tender Offer Deadline For Merger With Crown Laboratories To December 3, 2024 Amid Ongoing Discussions

BenzingaNov 29 06:25 ET

Express News | Revance Therapeutics Inc - Ongoing Discussions May Result in Further Delays or Modifications to Merger Agreement

ReutersNov 29 06:07 ET

Barclays Maintains Revance Therapeutics(RVNC.US) With Hold Rating, Maintains Target Price $7

Moomoo NewsNov 18 04:32 ET · Ratings

Barclays Remains a Hold on Revance Therapeutics (RVNC)

TipRanksNov 18 04:07 ET · Ratings

Mizuho Securities Maintains Revance Therapeutics(RVNC.US) With Hold Rating

Moomoo NewsNov 13 03:31 ET · Ratings

Cautious Hold Rating on Revance Therapeutics Amid Ongoing Merger Uncertainties With Crown Laboratories

TipRanksNov 13 02:45 ET · Ratings